MultiplexDX Showcases Innovation at SABCS 2025
MultiplexDX Showcases Innovation at SABCS 2025
MultiplexDX proudlyparticipated in the 48th San Antonio Breast Cancer Symposium (SABCS 2025),held December 9–12, 2025, in San Antonio, Texas, the world’s leadingscientific conference dedicated to breast cancer research and translationaloncology. The meeting brought together global experts in diagnostics, precisionmedicine, and breast cancer therapeutics to share the latest clinical and scientificadvances.
Our teamengaged with clinicians, researchers, and industry leaders to discuss thefuture of biomarker-driven treatment selection and next-generation moleculardiagnostics. A key milestone for the company was the presence of the first-everMultiplexDX exhibition booth at SABCS, representing an important step instrengthening our international visibility and expanding strategic partnershipswithin the global oncology community.
During the symposium, MultiplexDX highlighted theclinical potential of Multiplex8+, our advanced molecular platformdesigned to improve breast cancer classification, predict treatment response,and support more personalized therapeutic decision-making. Our participation atSABCS 2025 further reinforces MultiplexDX’s commitment to translatingcutting-edge science into clinically actionable solutions for patientsworldwide.
About MultiplexDX
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.
Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter
